Document:

Exhibit 10.2

 

EXECUTION VERSION

 

CONSULTING AGREEMENT

 

This Consulting
Agreement (this “Agreement”), dated September 29, 2017 is by and between Guardion Health Sciences, Inc., a Delaware
corporation (the “Company”), and David W. Evans (“Consultant”).

 

WHEREAS,
concurrently herewith, the Company and VectorVision Ocular Health, Inc., on the one hand, and VectorVision, Inc. (“VectorVision”)
and Consultant, on the other hand, are entering into that certain Asset Purchase and Reorganization Agreement, dated as of September
29, 2017 (the “Reorganization Agreement”), pursuant to which the Company will purchase certain assets of VectorVision,
as more particularly described in the Reorganization Agreement;

 

WHEREAS, execution
and delivery of this Agreement is a condition precedent to the consummation of the transactions contemplated by the Reorganization
Agreement;

 

WHEREAS,
VectorVision is engaged in the business of standardized vision testing for glare, contrast sensitivity and ETDRS acuity (the “Business”);

 

WHEREAS, upon
the closing of the Reorganization Agreement (the “Closing”), Consultant will become a member of the Board of
Directors of the Company;

 

WHEREAS, Consultant is an internationally
recognized expert, author and speaker and has considerable experience and expertise in the measurement of visual function related
to refractive surgery, glaucoma, eye diseases, visual performance and ocular blood flow.

 

WHEREAS, the
Company desires to retain Consultant to provide consulting services to the Company and its Affiliates (as defined below); and

 

WHEREAS, Consultant
is willing to provide such services in accordance with the terms and conditions of this Agreement.

 

NOW, THEREFORE,
in consideration of such engagement and the mutual covenants and promises herein contained, and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Company and Consultant agree as follows:

 

1.           Services.
During the Consulting Period, Consultant shall provide services to the Company and its Affiliates as described in Schedule
A attached hereto (the “Services”). Consultant shall use Consultant’s best efforts to perform
the Services such that the results are satisfactory to the Company. “Affiliate” of Company means any individual,
corporation, partnership, joint venture, limited liability company, unincorporated organization, trust, association or other entity
that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with,
Company. The term “control” (including the terms “controlled by” and “under common control with”)
means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of
an Affiliate, whether through the ownership of voting securities, by contract or otherwise.

 

    	 	-1-	 

     

    

 

2.           Compensation.
As consideration for the Services, the Company agrees to pay Consultant the fixed rate of Ten Thousand Dollars ($10,000) per month
for the first six (6) months of Services, and Seven Thousand Five Hundred Dollars ($7,500.00) per month for the remainder of the
Consulting Period (the “Fees”).

 

3.           Term.
The initial term of this Agreement shall be for three (3) years from the date of the Closing (the “Effective Date”)
(the “Initial Term”) and thereafter this Agreement shall automatically renew for additional twelve-month periods
(each such extension, a “Renewal Term”) unless the Company or Consultant provides written notice of non-renewal
to the other party at least thirty (30) days in advance of the expiration of the Initial Term or any Renewal Term, as applicable
(the Initial Term, together with any Renewal Term, the “Consulting Period”).

 

4.           Termination.
Consultant’s services hereunder may be terminated prior to the end of the Consulting Period as follows:

 

4.1          Automatically
in the event of the death of Consultant;

 

4.2          At
the option of the Company, on thirty (30) days prior written notice to Consultant or Consultant’s personal representative
in the event of the Disability of Consultant. As used herein, the term Disability shall mean Consultant’s becoming incapacitated
for a period of at least one hundred eighty (180) days by accident, sickness or other circumstance that renders Consultant mentally
or physically incapable of performing the material duties and services required of Consultant hereunder during such period;

 

4.3          At
the option of the Company for Cause (as defined in Section 5.4), immediately upon written notice to Consultant;

 

4.4          At
the option of the Company without Cause, on prior written notice to Consultant (provided that the assignment of this Agreement
to and assumption of this Agreement by the purchaser of all or substantially all of the assets of the Company shall not be treated
as a termination without Cause under this Section 4.4);

 

4.5          At
the option of Consultant in the event that Company (i) dissolves or (ii) files, or has filed against it, a petition for voluntary
or involuntary bankruptcy or pursuant to any other insolvency law, makes or seeks to make a general assignment for the benefit
of its creditors or applies for, or consents to, the appointment of a trustee, receiver or custodian for a substantial part of
its property;

 

4.6          At
any time after the completion of the Initial Term at the option of the Consultant, by providing one hundred twenty (120) days prior
written notice to the Company; or

 

4.7          By
mutual agreement of the parties.

 

    	 	-2-	 

     

    

  

5.           Payment
for Early Termination.

 

5.1          Termination
by the Company Without Cause. If Consultant’s services hereunder are terminated prior to the end of the Consulting Period
by the Company without Cause (and not due to death or Disability), subject to Section 5.5 hereof, Consultant shall be entitled
to:

 

(a)           within
thirty (30) days following such termination, payment of Consultant’s accrued and unpaid Fees and reimbursement of expenses
under Section 7 hereof in each case accrued through the date of termination; and

 

(b)           continuation
of Consultant’s Fees for the longer of: (i) the remainder of the then-current Initial Term or Renewal Term, as applicable,
or (ii) one (1) year (such longer period, the “Fee Continuation Period”), payable at the same time Fees would
have been paid if Consultant had continued to provide services to the Company or its Affiliates for the remainder of such Fee
Continuation Period; provided, however, if the Consultant’s review period for the release of claims required
pursuant to Section 5.5 hereof spans two of Consultant’s taxable years, the first payment shall be made on the first
regularly scheduled payroll date of the later taxable year following the effective date of such release of claims and shall include
any amounts due prior thereto.

 

5.2          Termination
due to Death or Disability. Upon the termination of Consultant’s services hereunder prior to the end of the Consulting
Period due to Consultant’s death or Disability pursuant to Section 4.1 or Section 4.2 respectively, Consultant
or Consultant’s legal representatives shall be entitled to receive the payments and benefits described under Section
6.1(a) hereof.

 

5.3          Termination
by the Company for Cause or Termination by Consultant. Except for the payments and benefits described in Section 5.1(a),
Consultant shall not be entitled to receive payments or benefits after the last date the Consultant provides services to the Company
or its Affiliates upon the termination of Consultant’s services hereunder prior to the end of the Consulting Period by the
Company for Cause pursuant to Section 4.3 or by Consultant pursuant to Section 4.5.

 

5.4          Cause.
For purposes of this Agreement, “Cause” shall mean:

 

(i)           Consultant’s
willful failure or refusal to perform the Services after being given written notice and thirty (30) days to remedy such failure
or refusal;

 

(ii)         Consultant’s
willful misconduct, gross negligence or breach of fiduciary duty in connection with Consultant’s performance of the Services;

 

(iii)        Consultant’s
act of dishonesty or breach of trust in connection with Consultant’s performance of the Services that is reasonably likely
to be materially injurious to the Company or its Affiliates or misappropriation of any assets or business opportunities of the
Company or its Affiliates;

 

(iv)        Consultant’s
conviction of, a plea of guilty or no contest to, or indictment for, any indictable criminal offence or any other criminal offence
involving fraud, dishonesty or misappropriation;

 

    	 	-3-	 

     

    

  

(v)         Consultant’s
conduct which is reasonably likely to injure the reputation or business of the Company, including, without limitation, any willful
violation by Consultant of any policies of the Company or its Affiliates;

 

(vi)        Consultant’s
breach of any confidentiality, non-solicitation or non- competition obligations to the Company, including, without limitation,
Section 8.1 of this Agreement;

 

(vii)       material
breach by Consultant of any of the provisions of this Agreement or any other agreement in effect between Consultant and the Company
which (if curable) is not cured within thirty (30) days of written notice; or

 

(viii)      as
provided in Section 12.1 hereof.

 

5.5          Conditions
to Payment. All payments due to Consultant under this Section 5 which are not otherwise required by law shall only
be payable if Consultant (or Consultant’s beneficiary or estate) delivers to the Company and does not revoke (under the
terms of applicable law) a general release of all claims in a form provided by the Company. Such general release shall be executed
and delivered (and no longer subject to revocation) within sixty (60) days following termination. Failure to timely execute and
return such release or revocation thereof shall be a waiver by Consultant of Consultant’s right to payment for the early
termination of the Consulting Period. In addition, payment for the early termination of the Consulting Period shall be conditioned
on Consultant’s compliance with Section 8 hereof.

 

6.           Reimbursement
of Expenses. The Company shall reimburse Consultant for Consultant’s reasonable and necessary expenses actually incurred
by Consultant directly in connection with Consultant’s performance of the Services hereunder, including, without limitation,
reasonable travel expenses, program attendance fees and membership fees, subject to appropriate substantiation and itemization
of such expenses in accordance with the guidelines and limitations established by the Company from time to time.

 

7.           Independent
Contractor Status. It is expressly understood by the Company and Consultant, and Consultant specifically requested, that
Consultant will be performing the Services under this Agreement as an independent contractor for the Company and that neither Consultant
nor any employee, representative, agent or subcontractor of Consultant is an employee or agent of the Company or its Affiliates.
Consultant shall not hold out himself as an employee, agent, partner or joint venture of the Company or its Affiliates. Consultant
will provide his own equipment and materials as may be required to perform the Services, will perform the Services at a location
of his choice, will set his own schedule for performing the Services (subject to interim and final deadlines for the delivery of
work product as may from time to time be stated by the Company), and will not be subject to the direction or control of the Company
or its Affiliates in conjunction with his performance of the Services (subject to specifications to be stated by the Company from
time to time relating to the work product) but will be subject to all decisions and actions of the Company’s Board of Directors.
Consultant will be solely responsible for all withholding and payment of taxes and similar charges related to the compensation
paid hereunder, as well as any applicable insurance, including but not limited to any worker’s compensation. The Company
will report all payments to Consultant hereunder via a Form 1099.

 

    	 	-4-	 

     

    

  

8.           Restrictions
on Activities of Consultant.

 

8.1          Non-Competition.
During the Consulting Term and either (i) the Fee Continuation Period, if Consultant’s Services are terminated by the Company
without Cause, or (ii) the one (1) year period commencing on the date Consultant ceases to provide the Services to the Company
or its Affiliates pursuant to this Agreement, if Consultant’s Services are terminated by the Company for any other reason
or by Consultant pursuant to Section 4.5 (the “Restriction Period”), Consultant covenants and agrees that Consultant
shall not directly or indirectly (whether for compensation or otherwise) own or hold any interest in, manage, operate, control,
consult with, render services for, or in any manner participate in, any Competitive Business, either as a general or limited partner,
proprietor, shareholder, officer, director, agent, employee, consultant, trustee, affiliate or otherwise. Nothing herein shall
prohibit Consultant from being a passive owner of not more than two percent (2%) of the outstanding securities of any publicly
traded company engaged in a Competitive Business. For purposes of this Agreement, “Competitive Business” shall
mean any business in the United States that the Company or, to Evan's knowledge, any of its Affiliates is conducting or is considering
conducting at the time Consultant’s services hereunder are terminated. For purposes of this Agreement, "Competitive
Business" shall not include any of the activities of listed on Section 3.23 of the Disclosure Schedule provided in connection
with the Reorganization Agreement.

 

8.2          Non-Solicitation.
Consultant covenants and agrees that during the Restriction Period, Consultant shall not directly or indirectly (i) influence
or attempt to influence or solicit any employees or independent contractors of the Company or any of its Affiliates to restrict,
reduce, sever or otherwise alter their relationship with the Company or such Affiliates, (ii) hire any employees or independent
contractors of the Company or any of its Affiliates, (iii) solicit or induce, or attempt to solicit or induce, any person or entity
that is a client, customer or business relation of the Company or any of its Affiliates to cease being a client, customer or business
relation of the Company or any of its Affiliates or to divert all or any part of such person or entity’s business from the
Company or any of its Affiliates, or (iv) assist any other person or entity in any way to do, or attempt to do, anything prohibited
by Sections 8.2(i), (ii), or (iii).

 

8.3          Confidentiality.

 

(a)           Consultant
shall not, during the Consulting Period or at any time thereafter directly or indirectly, disclose, reveal, divulge or communicate
to any person other than authorized officers, directors and employees of the Company or use or otherwise exploit for Consultant’s
own benefit or for the benefit of anyone other than the Company, any Confidential Information (as defined below). Consultant shall
not have any obligation to keep confidential any Confidential Information if and to the extent disclosure thereof is specifically
required by applicable law, court order or other legal or regulatory process; provided, however, that in the event disclosure is
required by applicable law, Consultant shall provide the Company with prompt notice, to the extent reasonably possible, of such
requirement prior to making any disclosure so that the Company may seek an appropriate protective order.

 

    	 	-5-	 

     

    

  

(b)           “Confidential
Information” means any information with respect to the Company or its Affiliates, including methods of operation, customer
lists, products, prices, fees, costs, technology, formulas, inventions, trade secrets, know-how, software, marketing methods,
plans, personnel, suppliers, competitors, markets or other specialized information or proprietary matters; provided, that,
there shall be no obligation hereunder with respect to, information that (i) is generally available to the public on the Effective
Date, (ii) becomes generally available to the public other than as a result of a disclosure not otherwise permissible hereunder,
or (iii) is required to be disclosed by law, court order or other legal or regulatory process and Consultant gives the Company
prompt written notice and the opportunity to seek a protective order.

 

8.4         Intellectual
Property and Ownership.

 

(a)           Intellectual
Property Rights Defined. Intellectual Property Rights (“IPR”) means all intellectual property or other similar
rights arising out of: (i) any patent or any application therefor and any and all reissues, divisions, continuations, renewals,
reexaminations, extensions, and continuations-in-part thereof; (ii) inventions (whether patentable or not in any country), invention
disclosures, industrial designs, improvements, trade secrets, proprietary information, know-how, technology, and technical data;
(iii) other proprietary rights in technology, including databases, software, all source and object code, algorithms, architecture,
structure, display screens, layouts, inventions, development tools, and all documentation and media constituting, describing, or
relating to the above, including, without limitation, manuals, memoranda, records, or business information, anywhere in the world;
(iv) any trademark or any application therefor; (v) any work of authorship; and (vi) any applications, registrations, provisional
applications, or other filings for, or to obtain, protect, perfect, or secure, any of the foregoing, anywhere in the world.

 

(b)           Sole
and Exclusive Benefit of Company. The Parties agree that all IPR that Consultant prepares, creates or otherwise develops (i)
under this Agreement, (ii) or in performing the Services, or (iii) for or related to the Business ("Consultant-Created
IPR"), is prepared for the sole and exclusive benefit of the Company and is the intellectual property of the Company.
The Parties agree that IPR solely prepared, created or developed in connection with Consultant’s other professional activities
identified in Section 3.23 of the Disclosure Schedule provided in connection with the Reorganization Agreement (“Excluded
IPR”) shall not constitute Consultant-Created IPR, provided, however, that in the event that any Excluded IPR has joint
applicability or relevance to the Business, such IPR shall constitute Consultant-Created IPR. Consultant shall sign such documents
and take such steps as the Company may reasonably require, at the cost and expense of the Company, to enable the Company to acquire,
perfect, and enforce its IPR and other legal protections for the Consultant-Created IPR, or to otherwise assist the Company in
securing the full benefit of the rights conferred in this Agreement. Unless otherwise agreed to in writing, the Company shall
have the sole and exclusive right to register all such Consultant-Created IPR in its name as the owner and author of such Consultant-
Created IPR.

 

(c)           Ownership
of Intellectual Property Rights. Company and Consultant further acknowledge and agree that all Consultant-Created IPR, any
existing IPR of the Company, and all IPR in the Business (“Company IPR”) are and shall become, upon creation,
the sole and exclusive property of Company. Company shall have and retain the right, but not the obligation, to seek, apply for
and obtain any or all copyrights, patents, registrations and similar protections which may be available or applicable to Company
IPR, including reissues, extensions, divisions, continuations, and continuations-in-part thereof. Consultant shall promptly disclose
in writing to Company each new development of Consultant-Created IPR and Excluded IPR as may be necessary to ensure Company’s
ownership of Company IPR. Consultant shall be bound to the terms of Section 8.3 in respect to Confidential Information related
to Company IPR.

 

    	 	-6-	 

     

    

  

(d)           Assignment.
Notwithstanding Sections 8.4(b) and 8.4(c) above, Consultant and Consultant’s heirs, assigns and representatives hereby irrevocably
assigns, transfers, and conveys to Company the sole and exclusive right, title, and interest in and to the Company IPR, including,
without limitation: (a) all patents, patent applications, copyrights, mask works, trade secrets, trademarks, and other Intellectual
Property Rights related to any of the Company IPR anywhere in the world, and (b) any and all Moral Rights (as defined below) that
Consultant may have in or with respect to any Company IPR. Consultant hereby forever waives and agrees never to assert any and
all Moral Rights that Consultant may have in or with respect to the Company IPR. For purposes of this Agreement, “Moral Rights”
shall mean any rights to claim authorship of the Company IPR, to object to or prevent the modification of any Company IPR, or to
withdraw from circulation or control the publication or distribution of any Company IPR, and any similar right, existing under
judicial or statutory law of any country in the world, or under any treaty, regardless of whether or not such right is denominated
or generally referred to as a “moral right.”

 

(e)           Whether
during or after the Consulting Period, Consultant further agrees to execute and acknowledge all papers and to do, at the Company’s
expense, any and all other things necessary for or incident to the applying for, obtaining and maintaining of such letters patent,
copyrights, trademarks or other intellectual property rights, as the case may be, and to execute, on request, all papers necessary
to assign and transfer such Company IPR to the Company and its successors and assigns. In the event that the Company is unable,
after reasonable efforts and, in any event, after ten (10) business days, to secure Consultant’s signature on a written assignment
to the Company, of any application for letters patent, trademark registration or to any common law or statutory copyright or other
property right therein, whether because of Consultant’s physical or mental incapacity, or for any other reason whatsoever,
Consultant irrevocably designates and appoints the Secretary of the Company as Consultant’s attorney-in-fact to act on Consultant’s
behalf to execute and file any such applications and to do all lawfully permitted acts to further the prosecution or issuance of
such assignments, letters patent, copyright or trademark.

 

8.5          Return
of Company Property. Within ten (10) days following the date of any termination of Consultant’s services, Consultant
or Consultant’s personal representative shall return all property of the Company or its Affiliates in Consultant’s
possession, including but not limited to all Company-owned computer equipment (hardware and software), smart phones, facsimile
machines, Blackberry, tablet computers and other communication devices, credit cards, office keys, security access cards, badges,
identification cards and all copies (including drafts) of any documentation or information (however stored) relating to the business
of the Company, its Affiliates, or customers and clients or prospective customers and clients of Company or its Affiliates. For
any property of the Company or its Affiliates not returned within such period, the Company may withhold the reasonable costs of
such property from Consultant’s Fees, at the Company’s sole discretion, until such property is returned. Anything
to the contrary notwithstanding, Consultant shall be entitled to retain (i) personal papers and other materials of a personal
nature, provided that such papers or materials do not include Confidential Information, (ii) information showing Consultant’s
compensation or relating to reimbursement of expenses, and (iii) copies of agreements relating to Consultant’s engagement,
or termination thereof, with the Company.

 

    	 	-7-	 

     

    

  

8.6          Maintenance
of Records. Consultant agrees to keep and maintain adequate, current, accurate, and authentic written records of all Consultant-Created
IPR made by Consultant (solely or jointly with others) during the term of this Agreement, and for a period of three (3) years
thereafter. The records will be in the form of notes, sketches, drawings, electronic files, reports, or any other format that
is customary in the industry and/or otherwise specified by the Company. Such records are and remain the sole property of the Company
at all times and upon Company’s request, Consultant shall deliver (or cause to be delivered) the same.

 

8.7          Non-Disparagement.
During the Consulting Period and at any time thereafter, the parties agree not to disparage or encourage or induce others to disparage
each other, any of their Affiliates or any of their respective past or present officers, directors, employees, products or services.
For purposes of this Section 8.7, the term “disparage” includes, without limitation, comments or statements
to the press, to the parties’ or their Affiliates’ employees or to any individual or entity with whom the the parties
or their Affiliates have a business relationship (including, without limitation, any vendor, supplier, customer or distributor),
or any public statement, that in each case is intended to, or can be reasonably expected to, materially damage any of the parties.
Notwithstanding the foregoing, nothing in this Section 8.7 shall prevent the parties from making any truthful statement
to the extent, but only to the extent (A) necessary with respect to any litigation, arbitration or mediation involving this Agreement,
including, but not limited to, the enforcement of this Agreement, in the forum in which such litigation, arbitration or mediation
properly takes place or (B) required by law, legal process or by any court, arbitrator, mediator or administrative or legislative
body (including any committee thereof) with apparent jurisdiction over any of the parties.

 

8.8          Cooperation.
During and following the Consulting Period, Consultant shall give Consultant’s assistance and cooperation willingly, upon
reasonable advance notice, in any matter relating to Consultant’s services to the Company or its Affiliates, or Consultant’s
knowledge as a result thereof as the Company may reasonably request, including Consultant’s attendance and truthful testimony
where deemed appropriate by the Company, with respect to any investigation or the Company’s defense or prosecution of any
existing or future claims or litigations or other proceeding relating to matters in which he was involved or had knowledge by
virtue of Consultant’s services to the Company. The Company will reimburse Consultant for reasonable out-of-pocket travel
costs and expenses incurred by him (in accordance with Company policy) as a result of providing such requested assistance, upon
the submission of the appropriate documentation to the Company.

 

8.9          No
Conflicting Obligations. Consultant represents and warrants that Consultant has no agreements, relationships, or commitments
to any other person or entity that conflict with the provisions of this Agreement, Consultant’s obligations to the Company
under this Agreement, and/or Consultant’s ability to perform the Services. Consultant will not enter into any such conflicting
agreement during the term of this Agreement. The parties acknowledge that Consultant's activities set forth in Section 3.23 of
the Disclosure Schedule provided in connection with the Reorganization Agreement shall not constitute such conflicting obligations.

 

8.10         Tolling.
In the event of any violation of the provisions of this Section 8, Consultant acknowledges and agrees that the post-termination
restrictions contained in this Section 8 shall be extended by a period of time equal to the period of such violation, it
being the intention of the parties hereto that the running of the applicable post-termination restriction period shall
be tolled during any period of such violation.

 

    	 	-8-	 

     

    

  

8.11         Survival.
This Section 8 shall survive any termination or expiration of this Agreement.

 

8.12         Obligations
Cumulative. The parties acknowledge and agree that the obligations and covenants contained in this Section 8 is in
addition to the obligations and covenants contained in the Reorganization Agreement.

 

9.           Enforcement
of Agreement. The parties acknowledge and agree that they would be irreparably damaged and continually injured if any
of the provisions of Section 8 are not performed in accordance with their specific terms and that any breach of Section
8 could not be adequately compensated by monetary damages alone. Accordingly, in addition to any other right or remedy to
which it may be entitled at law or in equity, the parties shall be entitled to enforce any provision of Section 8 by a
decree of specific performance and to temporary, preliminary and permanent injunctive or other appropriate equitable relief to
prevent breaches or threatened breaches of Section 8, without posting any bond or other security (to the extent permitted
by law) or showing or proving any actual damages, the inadequacy of money damages, likelihood of success on the merits or irreparable
harm or other undertaking. Further, the parties hereby waive any claim or defense that there is an adequate remedy at law for
such breaches or threatened breaches.

 

10.         Severability.
If any term or provision of this Agreement is invalid, illegal or unenforceable in any jurisdiction, such invalidity, illegality
or unenforceability shall not affect any other term or provision of this Agreement or invalidate or render unenforceable such term
or provision in any other jurisdiction. Upon such determination that any term or other provision is invalid, illegal or unenforceable,
the parties shall negotiate in good faith to modify this Agreement so as to affect the original intent of the parties as closely
as possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated
to the greatest extent possible.

 

11.         Notices.
All notices, consents and other communications required or permitted by this Agreement must be in writing and shall be (a)
delivered to the appropriate address by hand, by nationally recognized overnight service or by courier service (costs prepaid);
(b) sent by facsimile or e-mail; or (c) sent by registered or certified mail, return receipt requested, in each case to the following
addresses, facsimile numbers or e-mail addresses and marked to the attention of the Person (by name or title) designated below
(or to such other address, facsimile number, e-mail address or Person as a party may designate by notice to the other parties):

 

Consultant:

 

David W. Evans

4141 Jutland Drive, Suite 215

San Diego, CA 92117

Telephone: 937-548-7970

Facsimile: 937-548-2773

Email: devans@vectorvision.com

 

    	 	-9-	 

     

    

  

with a copy (which shall not constitute notice) to:

 

Robert W. Hicks

Robert W. Hicks & Associates

600 W. Broadway, Suite 700

San Diego, CA 92101

Telephone: 619-236-3403

Email: rhicks@rwhlaw.com

 

Company:

 

Guardion Health Sciences, Inc.

15150 Avenue of Science, Suite 200

San Diego, CA 92128

Attention: Michael Favish

Telephone: 858-605-9055 Ext 201

Facsimile: 858-630-5543

Email: mfavish@guardionhealth.com

 

with a copy (which shall not constitute notice) to:

 

SHEPPARD MULLIN RICHTER & HAMPTON LLP

 

333 South Hope Street, 43rd Floor

Los Angeles, CA 90071

Attention: David I. Sunkin, Esq.

Telephone: (213) 617-4252

Facsimile: (213) 443-2750

Email: dsunkin@sheppardmullin.com

 

All notices, consents, waivers
and other communications shall be deemed have been duly given (as applicable): if delivered by hand, when delivered by hand; if
delivered by overnight service, when delivered by nationally recognized overnight service; if delivered by courier, when delivered
by courier; if sent via registered or certified mail, three (3) business days after being deposited in the mail, postage prepaid;
or if delivered by email or facsimile, when transmitted if transmitted without indication of delivery failure prior to 5:00 p.m.
local time for the recipient (and if transmitted without indication of delivery failure after 5:00 p.m. local time for the recipient,
then delivery will be deemed duly given at 9:00 a.m. local time for the recipient on the subsequent business day, or upon earlier
acknowledgment, if acknowledged by the recipient).

 

12.          Miscellaneous.

 

12.1         Consultant
Representation. Consultant hereby represents to the Company that the execution and delivery of this Agreement by Consultant
and the Company and the performance by Consultant of Consultant’s duties hereunder shall not constitute a breach of, or
otherwise contravene, or be prevented, interfered with or hindered by, the terms of any other agreement or policy to which
Consultant is a party or otherwise bound, and further that Consultant is not subject to any limitation on his activities on behalf
of the Company or its Affiliates as a result of agreements into which Consultant has entered except for obligations of confidentiality
with former employers. To the extent this representation and warranty is not true and accurate, it shall be treated as a Cause
event and the Company may terminate Consultant’s services under this Agreement for Cause or not permit Consultant to commence
providing services under this Agreement.

 

    	 	-10-	 

     

    

  

12.2         No
Mitigation or Offset. In the event of any termination of Consultant’s services hereunder, Consultant shall be under
no obligation to seek other engagement or otherwise mitigate the obligations of the Company under this Agreement, and there shall
be no offset against amounts due Consultant under this Agreement on account of future earnings by Consultant.

 

12.3         Entire
Agreement. This Agreement supersedes all prior agreements, whether written or oral, between the parties hereto with respect
to its subject matter and constitutes, along with the Reorganization Agreement, a complete and exclusive statement of the terms
of the agreement between the parties with respect to the subject matter hereof.

 

12.4         Assignment
and Transfer. The provisions of this Agreement shall be binding on and shall inure to the benefit of the Company and any successor
in interest to the Company who acquires all or substantially all of the Company’s assets. The Company may assign this Agreement
to an Affiliate; provided, however, that, without Consultant’s consent, no such assignment shall relieve the Company of
its obligations hereunder. Neither this Agreement nor any of the rights, duties or obligations of Consultant shall be assignable
by Consultant, nor shall any of the payments required or permitted to be made to Consultant by this Agreement be encumbered, transferred
or in any way anticipated, except as required by applicable laws. All rights of Consultant under this Agreement shall inure to
the benefit of and be enforceable by Consultant’s personal or legal representatives, estates, executors, administrators,
heirs and beneficiaries. This Agreement is for the sole benefit of the parties and their respective successors and permitted assigns
and nothing herein, express or implied, is intended to or shall confer upon any other person or entity any legal or equitable
right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.

 

12.5         Modifications;
Waiver; Remedies Cumulative. No provision of this Agreement may be amended, supplemented, waived or otherwise modified except
by a written agreement executed by all the parties. The rights and remedies of the parties hereunder are cumulative and not alternative.
Neither any failure nor any delay by any party in exercising any right, power or privilege under this Agreement or any of the
documents referred to in this Agreement will operate as a waiver of such right, power or privilege, and no single or partial exercise
of any such right, power or privilege will preclude any other or further exercise of such right, power or privilege or the exercise
of any other right, power or privilege. To the maximum extent permitted by applicable law, (a) no waiver that may be given by
a party will be applicable except in the specific instance for which it is given, and (b) no notice to or demand on one party
will be deemed to be a waiver of any obligation of that party or of the right of the party giving such notice or demand to take
further action without notice or demand as provided in this Agreement.

 

    	 	-11-	 

     

    

  

12.6       Construction.
Unless the express context otherwise requires: (a) the words “hereof”, “herein”, and “hereunder”
and words of similar import, when used in this Agreement, shall refer to this Agreement as a whole and not to any particular provision
of this Agreement; (b) the terms defined in the singular have a comparable meaning when used in the plural, and vice versa; (c)
references herein to a specific Section shall refer to the Sections of this Agreement; (d) wherever the word “include,”
“includes,” or “including” is used in this Agreement, it shall be deemed to be followed by the words “without
limitation”; (e) any reference to the masculine, feminine or neuter gender shall include each other gender; and (f) any
reference to a party means a party to this Agreement. The parties agree that they have been represented by counsel during the
negotiation and execution of this Agreement and, therefore, waive the application of any applicable law or rule of construction
providing that ambiguities in an agreement or other document will be construed against the party or parties drafting such agreement
or document. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity
or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto,
and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any of the
provisions of this Agreement. Wherever a conflict exists between this Agreement and any other agreement, this Agreement shall
control but solely to the extent of such conflict.

 

12.7       Code
Section 409A.

 

(a)           The
parties agree that this Agreement shall be interpreted to comply with or be exempt from Section 409A of the Code and the regulations
and guidance promulgated thereunder to the extent applicable (collectively “Code Section 409A”), and all provisions
of this Agreement shall be construed in a manner consistent with the requirements for avoiding taxes or penalties under Code Section
409A. In no event whatsoever will the Company be liable for any additional tax, interest or penalties that may be imposed on Executive
under Code Section 409A or any damages for failing to comply with Code Section 409A.

 

(b)           For
purposes of Code Section 409A, Consultant’s right to receive any installment payments pursuant to this Agreement shall be
treated as a right to receive a series of separate and distinct payments. Whenever a payment under this Agreement specifies a
payment period with reference to a number of days (e.g., “payment shall be made within thirty (30) days following
the date of termination”), the actual date of payment within the specified period shall be within the sole discretion of
the Company.

 

12.8       Dispute
Resolution; Arbitration. If any contest or dispute arises between the parties with respect to this Agreement or Consultant’s
engagement or termination thereof, other than injunctive and equitable relief with regard to Section 9 hereof, such contest
or dispute shall be submitted to binding arbitration in San Diego, California in accordance with the rules and procedures of the
Commercial Arbitration Rules and the expedited arbitration procedures of the American Arbitration Association (“AAA”)
then in effect. The decision of the arbitrator shall be final and binding on the parties and may be entered in any court of applicable
jurisdiction. The parties shall split the fees of AAA and the arbitrator, which fees shall be recoverable as costs by the prevailing
party pursuant to Section 12.11.

 

    	 	-12-	 

     

    

  

12.9         Governing
Law. In all respects, including matters of construction, validity and performance, this Agreement shall be governed by, and
construed and enforced in accordance with, the internal laws of the State of California applicable to contracts made and performed
in that state (without regard to the choice of law or conflicts of law provisions thereof that would require the application of
the law of any other jurisdiction).

 

12.10        Attorneys’
Fees. If any action, including any arbitration pursuant to Section 12.9 or equitable action pursuant to Section 9 of this
Agreement, is brought for the enforcement of this Agreement, or because of an alleged dispute, breach, default or misrepresentation
in connection with any of the provisions of this Agreement, the successful or prevailing party shall be entitled to recover reasonable
attorneys’ fees (including in-house attorneys costs billed at reasonable rates) and other costs incurred in that action
from the non-prevailing party, in addition to any other relief to which it may be entitled.

 

12.11         Execution
of Agreement. This Agreement may be executed in counterpart signature pages executed and delivered via facsimile transmission
or via email with scan or email attachment. Any such counterpart executed and delivered via facsimile transmission or via email
with scan or email attachment will be deemed an original for all intents and purposes, and all such counterparts shall together
constitute one and the same instrument.

 

[SIGNATURE PAGE FOLLOWS]

 

    	 	-13-	 

     

    

  

IN
WITNESS WHEREOF, the parties hereto have duly executed this
Agreement as of the day and year
first above written.

 

	 	COMPANY
	 	 
	 	GUARDION HEALTH SCIENCES, INC.
	 	 
	 	/Michael Favish/
	 	Michael Favish 
	 	President
	 	 
	 	CONSULTANT
	 	 
	 	/David W. Evans/
	 	David W. Evans

 

Signature Page to Evans Consulting Agreement

 

     

     

    

  

SCHEDULE A

 

SERVICES

 

1.    Services:

 

Consultant will dedicate an adequate amount of his business
time to providing the services listed below, as well as on-going services as shall be identified by Company from time to time.

 

		·	Identifying and attending medical conferences, trade shows, leadership forums and other events or programs to advance Company’s
or an Affiliate’s business interests;

		·	Securing speaking engagements, leadership positions, industry expert appointments or other engagements within the medical field;

		·	Identifying, researching, facilitating and interfacing with investors and potential investors in Company’s or Affiliate’s
business;

		·	Creating introductions (potential partners, providers, etc.) for Company or Affiliates;

		·	Attending regular meetings of Company’s or Affiliates’ management team, as requested from time to time by Company;

		·	Conducting medical and scientific research in the field of and relating to the measurement of visual function related to refractive
surgery, glaucoma, eye diseases, visual performance and ocular blood flow;

		·	Writing and submitting scientific articles in the field of and relating to measurement of visual function related to refractive
surgery, glaucoma, eye diseases, visual performance and ocular blood flow;

		·	Performing other duties related to the Business as reasonably requested from time to time by Company.

 

    	 	-14-Exhibit 10.3

 

EXECUTION VERSION

 

INTELLECTUAL PROPERTY PURCHASE AGREEMENT

 

This intellectual property purchase
agreement (the "Agreement") is entered into as of September 29, 2017 (the "Effective Date"), by and between
David W. Evans, a US citizen (“Seller”) and Guardion Health Sciences, Inc., a Delaware corporation, or its assigns
(“Buyer”).

 

WHEREAS, Seller solely owns all
right, title, and interest in and to the patent applications listed in Schedule A attached hereto, any patents issuing therefrom,
and any patents or patent applications throughout the world claiming priority from any of the foregoing, including, without limitation,
all continuation patents, divisional patents, continuation-in-part patents, patent applications (including, without limitation,
provisional applications), reissues, reexaminations, extensions, substitutes and foreign counterparts concerning or relating to
said patents and patent applications, as well as any inventions disclosed in any of the foregoing (collectively, the “Patented
Technology”);

 

WHEREAS, Seller has not transferred,
licensed or otherwise encumbered Seller’s right, title and interest in the Patented Technology;

 

WHEREAS, Buyer desires to purchase
from Seller all right, title, and interest in and to the Patented Technology; and

 

WHEREAS Seller desires to sell
his right, title, and interest in and to the Patented Technology.

 

AGREEMENT

 

NOW, THEREFORE, in consideration
of the covenants and promises contained herein and for other good and valuable consideration, the receipt and sufficiency of which
is hereby acknowledged, the Parties hereby agree as follows:

 

1.     Definitions.

 

(a)          Covered
Goods or Services means goods or services sold or otherwise provided by Buyer to third parties that constitute a method and
apparatus for vision acuity testing that fall within the claims of the patents and patent applications included in the Patented
Technology.

 

(b)          Net
Revenues means the cash revenue of Buyer determined in accordance with United States generally accepted accounting principles
consistently applied with past practice (GAAP) for each Covered Good or Service that is sold anywhere in the world , after deduction
of the following: rebates, commissions, discounts, insurance, freight, duties, taxes and bad debts from amounts earlier booked
as revenue on sales of the Covered Goods or Services.

 

    	 	-1-	 

     

    

  

2.     Asset
Transfer. Seller hereby conveys, transfers, assigns, delivers, and contributes to Buyer all of Seller’s right, title,
and interest in and to the Patented Technology, including without limitation, damages, and payments for past or future infringements,
all rights to sue for past, present, and future infringements, and all other intellectual property rights owned or claimed by
Seller embodied in the Patented Technology, including renewal rights therein, the exclusive right to enforce and file related
patent applications therefor in the United States and throughout the world.

 

3.     Consideration.
As consideration for this Agreement, Buyer shall pay to Seller a commercially reasonable royalty (“Royalty”) of Net
Revenues during the Royalty Term (defined hereinafter). The Parties agree to negotiate the amount and the terms and conditions
of the Royalty in good faith, provided that the Parties agree and acknowledge that the Royalty for Covered Goods and Services
not covered by an issued patent shall be less than the Royalty for Covered Goods and Services covered by an issued patent. There
shall be no minimum requirements.

 

4.     Royalty
Term. Buyer’s payment of the Royalty to Seller shall begin thirty (30) days after the first sale or provision of the
Covered Goods or Services, if any, and remain in effect until the sooner of (a) the expiration of the last-to-expire of the Patented
Technology or

(b) the cessation of sales or provision of Covered
Goods or Services (“Royalty Term”).

 

5.     No
Obligation. Seller agrees and acknowledges that:

 

(a)          Subject
to Section 6, Buyer, in its sole and exclusive discretion, shall
(i) have the right, but not the obligation, to file or continue to
prosecute any patent application, secure any patent, or maintain any patent included in the Patented Technology; and (ii)
have the right, but not the obligation, to bring or prosecute actions or suits against any third parties for infringement of
the Patented Technology;

 

(b)          Buyer
(i) may engage in the conception, development, manufacture, use, practice, or sale of other products or methods which may compete
with the Covered Goods or Services, (ii) must contribute significant resources of its own to successfully develop, manufacture,
use, and sell the Covered Goods or Services; and (iii) may be obligated to submit certain notices and obtain certain approvals,
licenses and rights required by applicable law before it can develop, manufacture, use or sell the Covered Goods or Services, thus
Buyer shall only be required to use its reasonable efforts to develop, manufacture and sell the Covered Goods or Services; and

 

(c)          In
no event does Buyer guarantee that the Covered Goods or Services can or will be commercialized and Buyer may cease to commercialize,
develop or move forward with the Patented Technology at any time at its sole and exclusive discretion.

 

    	 	-2-	 

     

    

  

6.     In
the event that Buyer decides not to continue to prosecute the patent applications listed in Schedule A hereto (“Pending
Patent Applications”), or to otherwise commercially exploit the Patented Technology, Buyer shall give reasonable notice to
Seller of its decision. Buyer agrees to either notify Seller of its intent to not pursue the Pending Patent Applications at least
30 days prior to the expiration of any deadline in the US or foreign patent process or to otherwise timely comply with said deadlines.
In the event that Buyer decides not to pursue the Pending Patent Applications or continue to economically exploit the Patented
Technology, Seller shall have the right to require that the Pending Patent Applications and/or the Patented Technology, whichever
is applicable based on what Buyer decides not to pursue, be assigned back to Seller at no cost to Seller. In such event, Buyer
shall have an irrevocable, unrestricted, royalty free license (notwithstanding any royalty negotiated pursuant to this Agreement)
to practice any invention in such Pending Patent Applications should a patent be issued on such invention as needed by Buyer to
exploit the Covered Goods and Services to the extent their compositions or methods fall within the claims included in the Patented
Technology.

 

7.     Representations
and warranties.

 

Seller hereby represents and warrants that:

 

(a)          he
has not assigned, transferred, sold, conveyed any interest in, or otherwise disposed of his rights, title and interest in the Patented
Technology to anyone;

 

(b)          he
has sole, exclusive, valid, and unencumbered title to his rights, title and interest in the Patented Technology and has not granted
any liens, mortgages, encumbrances, licenses or other agreements thereon or thereto;

 

(c)          he
has full right, power and authority to grant all of the rights, title and interests granted in this Agreement, and no consents
of any other parties are necessary or appropriate under any agreements concerning the Patented Technology in order for the transfer
and assignment of any of his rights, title and interest in the Patented Technology under this Agreement to be legally effective;

 

(d)          no
dispute exists which challenges the use, legality, validity, or enforceability of the Patented Technology, and no circumstances
or grounds exist that would give rise to such disputes; and

 

(e)          to
Seller’s knowledge, use of the Patented Technology will not interfere with, infringe upon, misappropriate, or otherwise breach
the rights of any third party.

 

8.     Indemnity.
Seller shall indemnify, make good, save and hold harmless Buyer, its parent, successors, Buyers and assigns and their respective
officers, agents and employees, from all liabilities, damages, costs, charges, reasonable attorneys' fees, recoveries, actions,
judgments, penalties, expenses and other losses whatsoever which may be obtained against, imposed upon or suffered by Buyer,
its parent, successors, Buyers and assigns arising from a third party claim resulting from breach of any of Seller’s representations,
warranties or agreements hereunder.

 

    	 	-3-	 

     

    

  

9.     Successors
and Assigns. This Agreement shall be binding upon and shall inure to the benefit of the parties and their respective successors
and permitted assigns. No party may assign or delegate its rights or obligations hereunder without the prior written consent of
the other parties; provided, however, that Buyer shall be entitled to assign or delegate all or any part of its rights or obligations
hereunder (a) to any one or more affiliates of Buyer, (b) in connection with the sale of all or any substantial portion of the
assets of Buyer or one or more affiliates of Buyer or (c) for collateral security purposes to any lender providing financing to
Buyer. No assignment shall relieve the assigning party of any of its obligations hereunder. “Affiliate” of Buyer means
any individual, corporation, partnership, joint venture, limited liability company, unincorporated organization, trust, association
or other entity that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common
control with, Buyer. The term “control” (including the terms “controlled by” and “under common control
with”) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and
policies of an Affiliate, whether through the ownership of voting securities, by contract or otherwise.

 

10.   Further
Documents. The Parties shall execute all such further documents as shall be reasonable, convenient, necessary, or desirable
to carry out the provisions of the Agreement.

 

11.   Confidentiality.
The contents, but not the mere existence of this Agreement are and shall be kept confidential by the Parties.

 

12.   Amendment
and Modifications. Subject to applicable law, this Agreement may be amended, modified and supplemented only by written agreement
between the Parties hereto which states that it is intended to be a modification of this Agreement.

 

13.   Waiver
of Compliance. Any failure of either Party to comply with any obligation, covenant, agreement or condition herein may be expressly
waived in writing by the other party, but such waiver or failure to insist upon strict compliance with such obligation, covenant,
agreement or condition shall not operate as a waiver of, or estoppel with respect to, any subsequent or other failure.

 

14.   Waiver.
No failure on the part of any Party to exercise or delay in exercising any right hereunder shall be deemed a waiver thereof, nor
shall any single or partial exercise preclude any further or other exercise of such or any other right.

 

15.   Governing
Law, Jurisdiction and Venue. This Agreement shall be governed by and construed in accordance with the internal laws of the
State of Delaware without giving effect to any choice or conflict of law provision or rule (whether of the State of Delaware or
any other jurisdiction). Each party irrevocably consents and submits to the personal jurisdiction and venue of the federal and
state courts located in San Diego County, California and irrevocably waives any and all claims and defenses which such party might
otherwise have in any action or proceeding in any of such courts based upon any alleged lack of personal jurisdiction,
improper venue, forum non conveniens or any similar claim or defense. The prevailing party in any action brought pursuant to the
terms hereof shall be entitled to its attorneys’ fees and costs.

 

    	 	-4-	 

     

    

  

16.   Specific
Performance. The Parties agree that irreparable damage would occur in the event that any of the provisions of this Agreement
were not performed in accordance with their specific terms or were otherwise breached. Accordingly, in addition to any other right
or remedy to which it may be entitled at law or in equity, (a) Buyer will be entitled to seek an injunction or injunctions or
specific performance, without the posting of any bond, to prevent breaches of this Agreement by Seller and to enforce specifically
the terms and provisions of this Agreement, in addition to any other remedy to which such Party is entitled at law or in equity
and (b) Seller will be entitled to seek an injunction or injunctions or specific performance, without the posting of any bond,
to enforce specifically the terms and provisions of this Agreement, to prevent breaches of this Agreement, in addition to any
other remedy to which such Party is entitled at law or in equity.

 

17.   Dispute
Resolution; Arbitration. If any contest or dispute arises between the parties with respect to this Agreement, other than injunctive
and equitable relief with regard to Section 15 hereof, such contest or dispute shall be submitted to binding arbitration in Wilmington,
Delaware in accordance with the rules and procedures of the Commercial Arbitration Rules and the expedited arbitration procedures
of the American Arbitration Association (“AAA”) then in effect. The decision of the arbitrator shall be final and
binding on the parties and may be entered in any court of applicable jurisdiction. The parties shall bear their own legal fees
in any arbitration and shall split the fees of the AAA and the arbitrator.

 

18.   Counterparts.
This Agreement may be executed simultaneously in two or more counterparts, each of which shall be deemed an original, but all
of which together shall constitute one and the same instrument.

 

19.   Headings.
The headings of the Sections of this Agreement are inserted for convenience only and shall not constitute a part hereof or affect
in any way the meaning or interpretation of this Agreement.

 

20.   Third Parties.
Except as specifically set forth or referred to herein, nothing herein expressed or implied is intended or shall be construed
to confer upon or give to any person or corporation other than the Parties hereto and their successors or assigns, any rights
or remedies under or by reason of this Agreement.

 

21.   Severability.
If any provision of this Agreement is held by a court of competent jurisdiction to be unlawful or unenforceable, such provisions
shall be considered severed from the provisions of this Agreement but all remaining provisions of this Agreement shall remain
in full force and effect.

 

    	 	-5-	 

     

    

  

22.   Notices
and Demands. All notices, requests, demands or other communications required by, or otherwise with respect to this Agreement
shall be in writing and shall be deemed to have been duly given to any party when delivered personally (by courier service
or otherwise), against receipt, when delivered by telecopy and confirmed by return telecopy, or when actually received when mailed
by registered first-class mail, postage prepaid and return receipt requested in each case to the applicable addresses set forth
below:

 

Seller:

 

David W. Evans

4141 Jutland Drive, Suite 215

San Diego, CA 92117

Telephone: 937-548-7970

Facsimile: 937-548-2773

Email: devans@vectorvision.com

 

Buyer:

 

Guardion Health Sciences, Inc.

15150 Avenue of Science, Suite 200

San Diego, CA 92128

Attention: Michael Favish

Telephone: 858-605-9055 Ext 201

Facsimile: 858-630-5543

Email: mfavish@guardionhealth.com

 

with a copy (which shall not constitute notice) to:

 

SHEPPARD MULLIN RICHTER & HAMPTON LLP

333 South Hope Street, 43rd Floor

Los Angeles, CA 90071

Attention: David I. Sunkin, Esq.

Telephone: (213) 617-4252

Facsimile: (213) 443-2750

Email: dsunkin@sheppardmullin.com

 

23.  Entire
Agreement. This Agreement sets forth the final, complete and exclusive agreement and understanding of the Parties hereto in
respect of the subject matter contained herein, and supersedes all prior agreements, promises, covenants, arrangements, communications,
representations or warranties, whether oral or written, by any officer, employee or representative of any party hereto.

 

[Signature Page Follows]

 

    	 	-6-	 

     

    

  

IN
WITNESS WHEREOF, the Parties have caused this Agreement
to be executed and delivered to be effective as of the date first written above.

  

	Dated: September 29, 2017	Seller
	 	 
	 	/David Evans/
	 	David Evans
	 	Chief Executive Officer
	 	 
	Dated: September 29, 2017	Buyer
	 	 
	 	VectorVision Ocular Health, Inc.
	 	 
	 	/Michael Favish/
	 	Michael Favish
	 	President

 

Signature Page
to IP Purchase Agreement

 

     

     

    

  

SCHEDULE A

 

	Country	 	App. No.	 	Filing Date	 	Title
	USA	 	15277849	 	September 27, 2016	 	METHOD AND APPARATUS FOR VISION ACUITY TESTING
	USA	 	15445586	 	February 28, 2017	 	
        METHOD AND APPARATUS FOR

        VISION ACUITY TESTING

 

    	 	-8-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}]]